With this notice, Frontiers states its awareness of serious allegations surrounding the institutional review board Centro Internacional de Vacunas cited in this article. These allegations are being investigated in line with COPE guidelines. The situation will be updated as soon as the investigation is complete.
Summary
Keywords
Malaria, Plasmodium vivax, Multi-stage, Chimeric vaccine, transmission-blocking, p25
Citation
Frontiers Editorial Office (2023) Expression of concern: A multi-stage plasmodium vivax malaria vaccine candidate able to induce long-lived antibody responses against blood stage parasites and robust transmission-blocking activity. Front. Cell. Infect. Microbiol. 13:1292315. doi: 10.3389/fcimb.2023.1292315
Received
11 September 2023
Accepted
11 September 2023
Published
20 September 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2023
Updates
Copyright
© 2023 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.